TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06796101

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagus Nerve Stimulation
Description: In the study, CE certified vagus nerve stimulation device Vagustim will be used. Transcutaneous auricular vagus nerve stimulation will be applied bilaterally. The stimulation pulse width is 300 microseconds, frequency is 10 Hz and will be applied biphasically for 20 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled breathing exercises
Description: A controlled breathing exercise group will continue for a total of 2 weeks and will receive 10 sessions of 20 minutes per day.~The thoracic expansion exercise will be performed in 10 repetitions. In each intervention session, 2 sets of nadi shodhana pranayama consisting of 8 respiratory cycles will be applied to the patients, with a 2-minute rest period between the sets. Kapalabhati will be practised for 3 minutes, with 15 quick breaths in 10 seconds followed by a 20-second break (a total of 30 breaths per minute). In each session, 2 sets of bhramari pranayama consisting of 10 breathing cycles will be performed at a low respiratory rate, with a 1-minute rest period between sets. The physiological sigh exercise involves the first inspiration phase being 1 second, the second phase 0.25 seconds, and the exhalation 2 seconds for 3 minutes.
Study: NCT06563479

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Chemoradiation
Description: 30 Gy or 70 Gy of radiation in combination with standard chemotherapy (cisplatin, carboplatin, and 5-FU)

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Chemoradiation
Description: 70 Gy of radiation in combination with standard chemotherapy (cisplatin, carboplatin, and 5-FU)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessments
Description: EQ-5D-5L (5 questions); 2. MDADI-HN (total of 20 questions); 3. COST-FACIT (total of 12 questions).
Study: NCT06796790

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Media instruction
Description: Caregivers will be asked to implement joint media sessions with their child four times per week for 12 weeks using lightly adapted versions of the commercially-available Super Why! program, which focuses on early literacy skills, including alphabet knowledge, rhyming, spelling, and print concepts. Sessions are anticipated to last 20 minutes. Caregivers will be trained by researchers on explicit strategies to use to promote children's learning. Caregivers will digitally log every session and audio record 1 session each week

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Storybook intervention
Description: Caregivers will be asked to implement joint storybook reading sessions with their child four times per week for 12 weeks using adapted versions of the commercially -available Super-Why! storybooks, which focus on early literacy skills including alphabet knowledge, rhyming, spelling, and print concepts. Sessions are anticipated to last 20 minutes. Caregivers will be trained by researchers on explicit strategies to use to promote children's learning. Caregivers will digitally log every session and audio record 1 session each week.
Study: NCT06797050

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Training in reordering figurative stories with a social robot through the Learning by Teaching approach
Description: A test session of the 'picture sequencing' task with the social robot is planned. The selected children will undergo an initial neuropsychological, motor and school learning assessment and will be divided into Group 1 and Group 2: Group 1 (Experimental) will be offered training with the social robot, while Group 2 (Control) will continue standard care. Both groups will be re-evaluated after approximately about 4 months. After which Group 2 will be able to start treatment. After about 4 months, the children in both groups will again undergo the planned assessments. During the training, the child will be asked to help the social robot to reorder sequences of pictures from figurative stories in order to create a story that respects temporal or causal links, or motor actions of increasing complexity, according to the Learning by Teaching paradigm.
Study: NCT06795750

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neural therapy
Description: Neural therapy (NT) is a therapeutic intervention that uses local anesthetics to alleviate persistent musculoskeletal pain. NT targets the underlying autonomic dysfunction by modulating the autonomic nervous system. The enhancement of autonomic dysfunction leads to controlled microcirculation, the elimination of pain mediators, and the attainment of an anti-inflammatory effect. NT focuses on painful regions, specific segments of these areas, and trigger points, encompassing both local and segmental treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The second group received a home exercise program consisting of stretching, strengthening, and aerobic exercises for 30 minutes, three times per week, for a duration of five weeks.
Study: NCT06797141

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular Rehabilitation and Dual task Training and Traditional Physical Therapy
Description: Group A will receive treatment session lasting for 1 hour including vestibular rehabilitation therapy for 30 minutes and Dual Task Training for 20 minutes along with routine physical therapy of 10 minutes. Treatment session will be given 5 days per week for 8 weeks. Patients will be instructed to perform 2 sets of 5 repetition each Gaze Stability exercises: Horizontal and Vertical Head movements keep their eyes fixed on a stationary target, Following a slowly moving target keeping head still Balance Exercises:Maintain balance while performing neck rotations and shifting their weight forward, backward, and side to side.Sit to stand on chair Gait Training: Walking at varying speeds, walking forwards and backwards, sideways walking, walk in circles, and walking with horizontal and vertical head movements Dual Task exercises comprising of primary and secondary tasks Conventional Cawthorne Cooksey exercises :Up and down eye and Head movements, pick up things from ground, Walk up and down

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vestibular Rehabilitation and Traditional Physical Therapy
Description: Group B will receive treatment session lasting for 1 hour including vestibular rehabilitation therapy for 40 minutes along with routine physical therapy of 20 minutes. Treatment session will be given 5 days per week for 8 weeks.~Gaze Stability exercises: Horizontal and Vertical Head movements keep their eyes fixed on a stationary target, Following a slowly moving target keeping head still Balance Exercises:Maintain balance while performing neck rotations and shifting their weight forward, backward, and side to side.Sit to stand on chair Gait Training: Walking at varying speeds, walking forwards and backwards, sideways walking, walk in circles, and walking with horizontal and vertical head movements Conventional Cawthorne Cooksey exercises :Up and down eye and Head movements, pick up things from ground, Walk up and down
Study: NCT06793241

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 B-cell Acute Lymphoblastic Leukemia Targeted CAR T-cells injection
Description: Each subject receive CD19 B-cell Acute Lymphoblastic Leukemia Targeted CAR T-cells by intravenous infusion
Study: NCT06792799

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD19/BCMA CAR NK cells (KN5601)
Description: Patients will receive Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3. Multiple doses of anti-CD19 CAR NK cells (KN5601) will infused in each group using the 3 + 3 dose-escalation strategy.
Study: NCT06563479

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assessments
Description: EQ-5D-5L (5 questions); 2. MDADI-HN (total of 20 questions); 3. COST-FACIT (total of 12 questions).
Study: NCT06794775

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Adjuvant monotherapy with Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab + Ipilimumab
Description: Adjuvant combination therapy with Nivolumab and Ipilimumab
Study: NCT06793475

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-BCMA/GPRC5D bispecific CAR-T
Description: Autologous BCMA/GPRC5D bispecific CAR-T cells, infusion intravenously at a target dose of 2-4 x 10\^6 anti-BCMA/GPRC5D bispecific CAR-T cells/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apornemin
Description: Apornemin 10mg/kg will be administered by i.v. infusion. Apornemin will be administered on Days 1-5, 15-19 during bridging therapy, and on Days 1-5 every 28-day cycle during maintanance treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib 27mg/m\^2 will be administered by i.v. on Days 1,2,8,9 during bridging therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Thalidomide (150mg/d) will be administered by p.o. on Days 1-14 during bridging therapy, and Days 1-28 every 28-day cycle during maintanance treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone (20mg/d) will be administered by i.v. or p.o. on Days 1-4,8,9 during bridging therapy, and Days 1-4 during maintanance treatment.
Study: NCT06794632

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HANDY occupational therapy intervention
Description: The HANDY occupational therapy intervention is occupation-centred and follows the Occupational Therapy Intervention Process Model (OTIPM), specifying the steps of a problem-solving process focused on enabling performance of tasks in everyday life. The HANDY occupational therapy intervention consists of six mandatory sessions of 120 minutes representing a combination of individual and group sessions. Each group includes a maximum of eight participants with hand osteoarthritis, facilitated by two OTs.
Study: NCT06795932

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tendon Vibration
Description: Vibration can create kinesthetic illusions when applied at some modalities. The vibration will be put at 80 Hz and 1 mm of amplitude for 10 seconds to create 1 illusion/minute, during 20 minutes.~Two interventions per week, for three weeks. Total : 6 interventions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercices
Description: Standardized exercise protocol, performed daily for 3 weeks, with a diary.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Exercices
Description: Standardized exercise protocol, performed daily for 3 weeks, with a diary.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Tendon vibration
Description: Tendon vibration will not induce kinesthetic illusions, since it will be applied 40 Hz and 1 mm of amplitude for 10 seconds.~Two interventions per week, for three weeks. Total : 6 interventions
Study: NCT06793956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab and Linperlisib Combination Treatment
Description: Sintilimab administered via intravenous infusion; Linperlisib administered orally.
Study: NCT06795659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine (Intranasal Spray)
Description: Esketamine doses will be administered via insufflation with a starting dose of 1 spray of 14 mg per nostril (28 mg/total). Based on tolerability, total dose will be increased to a target dose of 84 mg delivered as three bouts separated by 5 minutes per bout (total dose administered in 15 minutes).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Massed Prolonged Exposure (PE)
Description: Eligible participants will be enrolled to receive 10 sessions of PE delivered in massed (daily) format over 2 weeks (weekdays, not including weekends and holidays)
Study: NCT06796933

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Silicon based products (silicon gel)
Description: The participants will be treated with cosmetic creams such as Silicone-based products (silicone gels twice a day) for one month.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Silicon based products (silicon gel)
Description: The participants will be treated with cosmetic creams such as Silicone-based products (silicone gels twice a day) for one month.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioptron (polarized light therapy)
Description: The participants will be treated by polarized light therapy (Bioptron) for 15 minutes, 3 sessions per week, for one month.
Study: NCT06794853

Intervention type: PROCEDURE
Intervention: Transjugular Intrahepatic Portosystemic Shunt
Description: All patients were treated with Transjugular Intrahepatic Portosystemic Shunt (TIPS).

Intervention type: PROCEDURE
Intervention: Transjugular Intrahepatic Portosystemic Shunt
Description: All patients were treated with Transjugular Intrahepatic Portosystemic Shunt (TIPS).
Study: NCT06792877

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Intervention
Description: The Mindfulness Intervention is an adapted form of Mindfulness-based stress reduction (MBSR) training virtual class that meets for 10 weeks. The class involves mindfulness training using awareness and focused attention, group discussion of the experience, and mindful movement. The Mindfulness Intervention also includes daily home practice using mindfulness recordings.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Waitlist then mindfulness
Description: Participants in this arm will first wait 10 weeks and then complete a mindfulness course with outcome measures assessed at baseline, after 10 weeks wait list and then after mindfulness course.
Study: NCT06634589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-16673
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-16673
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-16673
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-16673
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sonrotoclax
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sonrotoclax
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Administered orally
Study: NCT05011747

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: single-site rigid probe viscotrabeculotomy (VT)
Description: single-site VT by the rigid probe trabeculotome is performed through a superonasal triangular scleral flap.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: two-site rigid probe viscotrabeculotomy (VT)
Description: Two-site VT by the rigid probe trabeculotome is performed through a superonasal and an inferotemporal triangular scleral flap.
Study: NCT06272838

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biodex balance system
Description: In addition to the conventional exercise program, it will be applied on a platform with the Biodex balance system for 4 weeks, 5 days a week, in a total of 20 sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The conventional balance exercise program
Description: The conventional balance exercise program will be applied by a physiotherapist for 4 weeks, 5 days a week, in a total of 20 sessions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The conventional balance exercise program
Description: The conventional balance exercise program will be applied by a physiotherapist for 4 weeks, 5 days a week, in a total of 20 sessions.
Study: NCT05987319

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RadioFrequency Microneedling Device
Description: RadioFrequency device will be used for the treatment of dermatologic conditions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RadioFrequency Microneedling Device
Description: RadioFrequency device will be used for the treatment of dermatologic conditions.
Study: NCT06634589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Administered orally
Study: NCT06636227

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac 100mg
Description: Diclofenac 100mg
Study: NCT05791565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol HFA-152a
Description: Salbutamol HFA-152a will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol HFA-152a
Description: Salbutamol HFA-152a will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol HFA-134a
Description: Salbutamol HFA-134a will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol HFA-134a
Description: Salbutamol HFA-134a will be administered.
Study: NCT06163950

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fatigability assessment
Description: An isometric dynamometer will be used to assess fatigability development during a task to failure. Throughout the task, which consists of blocks of 3 minutes, neuromuscular assessments will take place to determine the evolution of fatigability and its peripheral and central determinants.
Study: NCT06636227

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac 75mg
Description: Diclofenac 75mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac 50mg
Description: Diclofenac 50mg
Study: NCT05187715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 40mg
Description: Simvastatin 40mg OD

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical Treatment
Description: Standard medical Treatment eccluding pentoxiphylline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard medical Treatment
Description: Standard medical Treatment eccluding pentoxiphylline
Study: NCT06636227

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Placebo control
Study: NCT06791473

Intervention type: DIAGNOSTIC_TEST
Intervention: AI-Based Diagnostic and Prognostic Model
Description: This intervention involves an AI system that integrates multimodal data, including patient medical history, laboratory test results, imaging data, and genetic information, to predict the risk of cancer. The system uses deep learning algorithms to provide real-time, accurate predictions, enabling early identification of cancer risks. By analyzing historical health data, the model aims to predict potential cancer developments, improving early detection and treatment outcomes.

Intervention type: DIAGNOSTIC_TEST
Intervention: AI-Based Diagnostic and Prognostic Model
Description: This intervention involves an AI system that integrates multimodal data, including patient medical history, laboratory test results, imaging data, and genetic information, to predict the risk of cancer. The system uses deep learning algorithms to provide real-time, accurate predictions, enabling early identification of cancer risks. By analyzing historical health data, the model aims to predict potential cancer developments, improving early detection and treatment outcomes.
Study: NCT06797791

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multifocal Continuous Theta Burst Transcranial Magnetic Stimulation
Description: The experimental stimulation protocol included 3 trains of cTBS with an inter-train interval of 10 min. Each train of cTBS consisted of 600 pulses applied in blocks at the theta frequency (200ms) with a duration of 40 s. A block of pulses consisted of 3 pulses at 50Hz frequency, stimulus intensity being estimated as 80% of the RMT. Stimulation application was performed by positioning the Magventure MMC-140 coil over the vertex (Cz) according to the 10-20 EEG system overlapping bilateral motor and somatosensory cortical areas.
Study: NCT06794294

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection allogenic Umbilical Cord-derived Mesenchymal Stem Cell
Description: Biological: Allogenic Umbilical Cord - derived Mesenchymal Stem Cell~1. Injection dosage and volume of the study drugs:~   * Low dose: 1x10⁷ cells/3mL~2. Number of injections: Only once during the study period~3. Device: Ultrasound~4. Injection technique: Injection into the lesion by investigator~Biological: Allogenic Umbilical Cord - derived Mesenchymal Stem Cell~1. Injection dosage and volume of the study drugs:~   * Mid dose: 5x10⁷ cells/3mL~2. Number of injections: Only once during the study period~3. Device: Ultrasound~4. Injection technique: Injection into the lesion by investigator~Biological: Allogenic Umbilical Cord - derived Mesenchymal Stem Cell~1. Injection dosage and volume of the study drugs:~   * High dose: 1x10e8 cells/3mL~2. Number of injections: Only once during the study period~3. Device: Ultrasound~4. Injection technique: Injection into the lesion by investigator
Study: NCT04797767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Given IV
Study: NCT06204237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [89Zr]Zr-DFO-APAC
Description: All participants will receive a single i.v. injection of \[89Zr\]Zr-DFO-APAC 15 MBq (Megabecquerel).
Study: NCT04797767

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Granulocyte Colony-Stimulating Factor
Description: Given subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT06204237

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET/CT scan
Description: The IMP administration will be followed by whole-body PET/CT scanning (day 1), and repeated PET/CT scans on days 3 and 7.
Study: NCT06797401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBD5044
Description: RBD5044, active drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBD5044
Description: RBD5044, active drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBD5044
Description: RBD5044, active drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo that is identical in appearance and volume to the doses of active IMP.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo that is identical in appearance and volume to the doses of active IMP.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo that is identical in appearance and volume to the doses of active IMP.
Study: NCT06795204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK3486
Description: Study Drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin Hydrochloride
Description: Positive Control

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Negative Control
Study: NCT06795867

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: acceptance and commitment therapy
Description: a 'third wave behavioral management